Direct from the C-Suite: CDMO Operations in a Covid-19 World - John Fowler, COO

The investment covers two expansions to accommodate several pipeline products moving to commercial scale

The move is expected to bring added value to customers by coupling biology services with existing chemistry capabilities

Transaction adds new technologies and capabilities in large molecules, including vaccines and gene therapy, to its global offering

Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.

Partnering with a CDMO that provides Integrated Services offers significant benefits to pharma and biotech innovators in the areas of efficiency, speed-to-market and access to unique expertise. In this white paper entitled “INTEGRATED SERVICES: PARTNERSHIPS FOR SUCCESS” we explore why integration matters and present the key components for success.

 

Embracing a patient-focused ideology represents a massive change for a CDMO. In this new white paper, “PATIENT CENTRICITY: A COMPASSIONATE APPROACH THAT PUTS PATIENTS AT THE FOREFRONT OF OUR MISSION,” we take an in-depth look at what the concept means, how it is driving organizational development, and its effect on employee awareness of our how our work impacts lives.

In this session you will hear from Stuart Needleman, CCO & Chief Patient Centricity Officer from Piramal Pharma Solutions